What is claimed is:
1. A method of screening a preparation comprising hCG or an hCG chain or hCG chain or a derivative of hCG or of said alpha or -hCG chain, for anti-HIV activity comprising assaying said preparation for the ability to inhibit HIV replication or expression of HIV RNA or protein.
2. The method of claim 1 in which the preparation is assayed by a method comprising measuring HIV-1 p24 antigen levels in cultured hematopoietic cells acutely infected with HIV-1, which cells have been contacted with the preparation; and comparing the measured HIV-1 p24 antigen levels in the cells which have been contacted with the hCG preparation with said levels in cells not so contacted with the preparation, wherein a lower level in said contacted cells indicates that the preparation has anti-HIV activity.
4. The method of claim 1 in which the preparation includes a peptide comprising a -hCG (SEQ ID NO:2) segment selected from the group consisting of 41-54, 45-54, 47-53, 45-58, 41-53, 42-53, 43-53, 44-53, 44-57, 45-53, 46-53, 45-55, 45-56, 47-54, 47-56, 47-58, and 58-145 (SEQ ID NOS: 3-5, 18, 8-14, 16, 17, 19, 21, 22 and 24, respectively), wherein said segment is not flanked by natively occurring -hCG sequences.
5. The method of claim 1 in which the preparation includes a peptide (A) consisting essentially of a -hCG (SEQ ID NO:2) segment selected from the group consisting of 41-54, 45-54, 47-53, 45-58, 41-53, 42-53, 43-53, 44-53, 44-57, 45-53, 46-53, 45-55, 45-56, 47-54, 47-56, 47-58, and 58-145 (SEQ ID NOS: 3-5, 18, 8-14, 16, 17, 19, 21, 22 and 24, respectively); and (B) excluding -hCG (SEQ ID NO:2) amino acids contiguous to said segment.
6. The method of claim 1 in which the preparation includes a peptide comprising a -hCG (SEQ ID NO:2) segment selected from the group consisting of 41-54, 45-54, 47-53, 45-57, 45-58, 41-53, 42-53, 43-53, 44-53, 44-57, 45-53, 46-53, 45-54, 45-55, 45-56, 47-54, 47-56, 47-58, 48-145, or 58-145 (SEQ ID NOS: 3-6, 18, 8-17, and 19-24, respectively).
7. The method of claim 1 in which the preparation is assayed by a method comprising measuring the activity of a reporter gene product expressed from a construct in which the HIV-1 LTR is operably linked to said reporter gene, wherein said construct is present in cultured cells which have been contacted with the preparation; and comparing the measured expression of said reporter gene in the cells which have been contacted with the preparation with said levels in such cells not so contacted, wherein a lower level in said contacted cells indicates that the preparation has anti-HIV activity.
8. The method of claim 1 in which the preparation is assayed by a method comprising measuring HIV-1 derived RNA transcripts or HIV-1 antigen levels in HIV-1 transgenic mice administered the preparation; and comparing the measured transcript or antigen levels in the mice which have been administered the preparation with said levels in mice not so administered, wherein a lower level in said administered mice indicates that the preparation has anti-HIV activity.
9. The method of claim 1 in which the preparation is assayed by a method comprising measuring SIV p27 antigen levels in the peripheral blood mononuclear cells of SIV infected monkeys administered the preparation; and comparing the measured antigen levels in the monkeys which have been administered the preparation with said levels in monkeys not so administered, wherein a lower level in said administered monkeys indicates that the preparation has anti-HIV activity.
10. A method of treating or preventing HIV infection in a subject in need of such treatment or prevention, comprising administering to the subject an amount of a composition effective to treat or prevent HIV infection, wherein said composition (i) is administered by gene therapy, and (ii) includes a peptide comprising a -hCG (SEQ ID NO:2) segment selected from the group consisting of 41-54, 45-54, 47-53, 45-58, 41-53, 42-53, 43-53, 44-53, 44-57, 45-53, 46-53, 45-55, 45-56, 47-54, 47-56, 47-58, and 58-145 (SEQ ID NOS: 3-5, 18, 8-14, 16, 17, 19, 21, 22 and 24, respectively), wherein said segment is not flanked by natively occurring -hCG sequences.
11. A method of treating or preventing HIV infection in a subject in need of such treatment or prevention, comprising administering to the subject an amount of a composition effective to treat or prevent HIV infection, wherein said composition (i) is administered by gene therapy, and (ii) includes a peptide (A) consisting essentially of a -hCG (SEQ ID NO:2) segment selected from the group consisting of 41-54, 45-54, 47-53, 45-58, 41-53, 42-53, 43-53, 44-53, 44-57, 45-53, 46-53, 45-55, 45-56, 47-54, 47-56, 47-58, and 58-145 (SEQ ID NOS: 3-5, 18, 8-14, 16, 17, 19, 21, 22 and 24, respectively); and (B) excluding -hCG (SEQ ID NO:2) amino acids contiguous to said segment.
12. A method of treating or preventing HIV infection in a subject in need of such treatment or prevention, comprising administering to the subject an amount of a composition effective to treat or prevent HIV infection, wherein said composition (i) is administered by gene therapy, and (ii) includes a peptide comprising a -hCG (SEQ ID NO:2) segment selected from the group consisting of 41-54, 45-54, 47-53, 45-57, 45-58, 41-53, 42-53, 43-53, 44-53, 44-57, 45-53, 46-53, 45-54, 45-55, 45-56, 47-54, 47-56, 47-58, 48-145, or 58-145 (SEQ ID NOS: 3-6, 18, 8-17, and 19-24, respectively).
13. A pharmaceutical composition comprising a therapeutically effective amount of a purified nucleic acid encoding -hCG or a derivative of -hCG; and a pharmaceutically acceptable carrier.
14. The pharmaceutical composition of claim 13 in which the purified nucleic acid encodes a derivative of -hCG comprising a -hCG (SEQ ID NO:2) segment selected from the group consisting of 41-54, 45-54, 47-53, 45-58, 41-53, 42-53, 43-53, 44-53, 44-57, 45-53, 46-53, 45-55, 45-56, 47-54, 47-56, 47-58, and 58-145 (SEQ ID NOS: 3-5, 18, 8-14, 16, 17, 19, 21, 22 and 24, respectively) wherein said segment is not flanked by natively occurring -hCG sequences.
15. The pharmaceutical composition of claim 13 in which the purified nucleic acid encodes a derivative of -hCG comprising a -hCG (SEQ II) NO:2) segment selected from the group consisting of 41-54, 45-54, 47-53, 45-58, 41-53, 42-53, 43-53, 44-53, 44-57, 45-53, 46-53, 45-55, 45-56, 47-54, 47-56, 47-58, and 58-145 (SEQ ID NOS: 3-5, 18, 8-14, 16, 17, 19, 21, 22 and 24, respectively); and (B) excluding -hCG (SEQ ID NO:2) amino acids contiguous to said segment.
16. The pharmaceutical composition of claim 13 in which the purified nucleic acid encodes a derivative of -hCG comprising a -hCG (SEQ ID NO:2) segment selected from the group consisting of 41-54, 45-54, 47-53, 45-57, 45-58, 41-53, 42-53, 43-53, 44-53, 44-57, 45-53, 46-53, 45-54, 45-55, 45-56, 47-54, 47-56, 47-58, 48-145, or 58-145 (SEQ ID NOS: 3-6, 18, 8-17, and 19-24, respectively).
17. The pharmaceutical composition of claim 13 in which the nucleic acid is a nucleic acid vector.
18. A pharmaceutical composition comprising a recombinant cell containing a nucleic acid vector encoding -hCG or a derivative of -hCG; and a pharmaceutically acceptable carrier.
19. The pharmaceutical composition of claim 18 in which the nucleic acid encodes a derivative of -hCG comprising a -hCG (SEQ ID NO:2) segment selected from the group consisting of 41-54, 45-54, 47-53, 45-58, 41-53, 42-53, 43-53, 44-53, 44-57, 45-53, 46-53, 45-55, 45-56, 47-54, 47-56, 47-58, and 58-145 (SEQ ID NOS: 3-5, 18, 8-14, 16, 17, 19, 21, 22 and 24, respectively) wherein said segment is not flanked by natively occurring -hCG sequences.
20. The pharmaceutical composition of claim 18 in which the nucleic acid encodes a derivative of -hCG comprising a -hCG (SEQ ID NO:2) segment selected from the group consisting of 41-54, 45-54, 47-53, 45-58, 41-53, 42-53, 43-53, 44-53, 44-57, 45-53, 46-53, 45-55, 45-56, 47-54, 47-56, 47-58, and 58-145 (SEQ ID NOS: 3-5, 18, 8-14, 16, 17, 19, 21, 22 and 24, respectively); and (B) excluding -hCG (SEQ ID NO:2) amino acids contiguous to said segment.
21. The pharmaceutical composition of claim 18 in which the nucleic acid encodes a derivative of -hCG comprising a -hCG (SEQ ID NO:2) segment selected from the group consisting of 41-54, 45-54, 47-53, 45-57, 45-58, 41-53, 42-53, 43-53, 44-53, 44-57, 45-53, 46-53, 45-54, 45-55, 45-56, 47-54, 47-56, 47-58, 48-145, or 58-145 (SEQ ID NOS: 3-6, 18, 8-17, and 19-24, respectively).
22. The pharmaceutical composition of claim 18 in which the cell is a hematopoietic cell.
23. A nucleic acid that encodes a peptide, wherein said peptide is selected from the group consisting of:
(a) peptides comprising a -hCG (SEQ ID NO:2) segment selected from the group consisting of 41-54, 45-54, 47-53, 45-58, 41-53, 42-53, 43-53, 44-53, 44-57, 45-53, 46-53, 45-55, 45-56, 47-54, 47-56, 47-58, and 58-145 (SEQ ID NOS: 3-5, 18, 8-14, 16, 17, 19, 21, 22 and 24, respectively), wherein said segment is not flanked by natively occurring -hCG sequences;
(b) peptides consisting essentially of a -hCG (SEQ ID NO:2) segment selected from the group consisting of 41-54, 45-54, 47-53, 45-58, 41-53, 42-53, 43-53, 44-53, 44-57, 45-53, 46-53, 45-55, 45-56, 47-54, 47-56, 47-58, and 58-145 (SEQ ID NOS: 3-5, 18, 8-14, 16, 17, 19, 21, 22 and 24, respectively); and (B) excluding -hCG (SEQ ID NO:2) amino acids contiguous to said segment; and
(c) peptides comprising a -hCG (SEQ ID NO:2) segment selected from the group consisting of 41-54, 45-54, 47-53, 45-57, 45-58, 41-53, 42-53, 43-53, 44-53, 44-57, 45-53, 46-53, 45-54, 45-55, 45-56, 47-54, 47-56, 47-58, 48-145, or 58-145 (SEQ ID NOS: 3X, 18, 8-17, and 19-24, respectively).
24. A method of treating or preventing HIV infection in a human subject in need of such treatment or prevention comprising administering to the subject a therapeutic agent selected from the group consisting of:
(a) a recombinant cell as in claim 18; and
(b) a nucleic acid as in claim 23.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A hydromechanical transmission comprising:
a first planetary having first, second and third elements;
a second planetary having first, second and third elements connected to the first planetary;
a hydrostatic transmission connected to the first and second planetaries;
a first clutch connected to the first element of the second planetary and the third element of the first planetary;
a second clutch connected to the first element of the second planetary; wherein the clutches are sequentially engaged to create first and second forward operating modes.
2. The hydromechanical transmission of claim 1 further comprising:
an input connected to the third element of the second planetary;
an output connected to the third element of the first planetary; and
wherein the hydrostatic transmission has first and second hydrostatic units wherein the second hydrostatic unit is connected to the input and the third element of the second planetary.
3. The hydromechanical transmission of claim 1 further comprising a reverse clutch connected to the first element of the second planetary and a ground.
4. The hydromechanical transmission of claim 1 wherein the second clutch is connected to the third element of the second planetary.
5. The hydromechanical transmission of claim 1 further comprising a third clutch connected to the first planetary that is sequentially engaged in association with the first and second clutches to create a third forward operating mode.
6. The hydromechanical transmission of claim 1 further comprising an engine providing an input directly connected to the second planetary.
7. The hydromechanical transmission of claim 1 further comprising a third planetary having first, second and third elements wherein the first element of the third planetary is connected to the third element of the first planetary, the second element of the third planetary is connected to the second element of the first planetary with a third clutch and the third element of the third planetary is connected to an input.
8. A hydromechanical transmission comprising:
a hydrostatic transmission having first and second rotational shafts;
a first planetary having first, second and third elements wherein the first rotational shaft is connected to the second element of the first planetary;
said second rotational shaft connected to an input;
a second planetary having first, second and third elements wherein the third element of the second planetary is connected to the input;
a first, second and reverse clutch connected to the first element of the second planetary such that when selectively engaged the first, second and reverse clutches create first, second and third forward operating modes each having a continuous ratio.
9. The hydromechanical transmission of claim 8 further comprising an output connected to the third element of the first planetary.
10. The hydromechanical transmission of claim 8 wherein the first clutch is connected to the third element of the first planetary.
11. The hydromechanical transmission of claim 8 wherein the reverse clutch is connected with ground.
12. The hydromechanical transmission of claim 8 wherein the reverse clutch is connected to the third element of the first planetary with a reducing gear.
13. The hydromechanical transmission of claim 8 wherein the first element of the first planetary is connected to the second element of the second planetary.
14. The hydromechanical transmission of claim 8 wherein the second clutch is additionally connected to the third element of the second planetary.
15. The hydromechanical transmission of claim 8 further comprising:
a third planetary having first, second and third elements wherein the third element of the third planetary is connected to the third element of the second planetary, the first element of the third planetary is connected to the third element of the first planetary; and
a third clutch between the second element of the third planetary and the second element of the first planetary.
16. The hydromechanical transmission of claim 15 wherein there is a negative ratio between the first element of the third planetary and the third element of the first planetary, and a positive ratio between the second element of the third planetary and the second element of the first planetary.
17. The hydromechanical transmission of claim 8 wherein the hydrostatic transmission comprises a variable unit and a fixed unit wherein the variable unit changes displacement from a starting displacement to a negative of the starting displacement in the first, second and third forward operating modes.
18. The hydromechanical transmission of claim 17 wherein the variable unit does not change displacement during a mode change.
19. A hydromechanical transmission comprising:
an input having an input center line and an output having an output center line parallel to the input centerline;
a first planetary having a first, second and third elements wherein the output is connected to the first planetary;
a second planetary located on the input center line and having first, second and third elements wherein the third element of the second planetary is connected to the input; and
first, second and reverse clutches connected to the second planetary such that when sequentially engaged first, second and third forward operating modes with continuous ratios are created.
20. The hydromechanical transmission of claim 19 wherein the second element of the second planetary is connected to the first element of the first planetary.
21. The hydromechanical transmission of claim 19 wherein the first, second and reverse clutches are adjacent.
22. The hydromechanical transmission of claim 19 wherein the input extends through the transmission for a power takeoff.
23. The hydromechanical transmission of claim 19 wherein the output extends through the transmission to provide drive at both ends of the transmission.
24. The hydromechanical transmission of claim 19 wherein at least one of the elements of the first and second planetaries is a sun gear having a speed that is greater than speeds of the other elements.
25. The hydromechanical transmission of claim 19 wherein the reverse clutch connects the third element of the first planetary with the first element of the second planetary and a reduction gear.
26. The hydromechanical transmission of claim 19 wherein a third planetary is located on the output center line and has first, second and third elements wherein the third element of the third planetary is connected to the input, the second element of the third planetary is connected to the second element of the first planetary with a third clutch and the first element of the third planetary is connected to the third element of the first planetary.